- Thymalfasin
-
- $10.00 / 1ASSAYS
-
2026-04-30
- CAS:69440-99-9
- Min. Order: 1ASSAYS
- Purity: 99%
- Supply Ability: 1 ton
- Thymalfasin
-
- $0.00 / 1g
-
2026-04-30
- CAS:69440-99-9
- Min. Order: 1g
- Purity: 0.99
- Supply Ability: 1000kg
- Thymalfasin
-
- $0.00 / 1g
-
2026-04-30
- CAS:69440-99-9
- Min. Order: 1g
- Purity: 98%min
- Supply Ability: 1000g
|
| | Thymalfasin Basic information |
| Product Name: | Thymalfasin | | Synonyms: | Thymalfasin;L-Asparagine, N-acetyl-L-seryl-L-alpha-aspartyl-L-alanyl-L-alanyl-L-valyl-L-alpha-asparatyl-L-threonyl-L-seryl-L-seryl-L-alpha-glutamyl-L-isoleucyl-L-threonyl-L-threonyl-L-lysyl-L-alpha-aspartyl-L-leucyl-L-lysyl-L-alpha-glutamyl-L-lysyl-L-lysyl-L-alpha-glutamyl-L-valyl-L-valyl-L-alpha-glutamyl-L-alpha-glutamyl-L-alanyl-L-alpha-glutamyl-;Thymosin alpha1 (cattle);Thymosin alpha1 (human);Thymosin alpha1 (ox);PubChem ID: 16130571;The thymus method sheen;ThymalfasinQ: What is
Thymalfasin Q: What is the CAS Number of
Thymalfasin Q: What is the storage condition of
Thymalfasin Q: What are the applications of
Thymalfasin | | CAS: | 69440-99-9 | | MF: | C129H215N33O55 | | MW: | 0 | | EINECS: | 1592732-453-0 | | Product Categories: | API;69440-99-9 | | Mol File: | Mol File | ![Thymalfasin Structure]() |
| | Thymalfasin Chemical Properties |
| | Thymalfasin Usage And Synthesis |
| Uses | Zadax-
in (SciClone). | | Uses | Chronic hepatitis B and Chronic hepatitis C | | Uses | Thymalfasin is an important peptide drug widely used for the single or combination treatment of hepatitis, sepsis, cancer, and immunodeficiency. | | Definition | ChEBI: Thymalfasin is a polypeptide. | | Brand name | Zadaxin | | Biological Functions |
Thymalfasin is a 28-amino acid peptide with immunomodulatory activity that has demonstrated therapeutic potential in a variety of diseases, including viral hepatitis. It enhances T-cell function, exhibits antiviral activity and increases intracellular glutathione levels. This is primarily manifested in its ability to promote T-cell differentiation and/or maturation, increase the production of interferon-gamma (IFN-γ), IL-2 and IL-3, enhance natural killer (NK) cell activity, and promote the production of migration inhibitory factor (MIF). In vitro studies indicate that it counteracts T-cell apoptosis in thymocytes. Its antiviral action involves inhibiting viral replication by increasing the expression of MHC class I molecules and reducing viral replication in infected cells cultured in vitro. Thymalfasin also elevates intracellular glutathione levels, and this increase in glutathione is crucial for significantly reducing viral replication[1].
| | General Description | Thymalfasin (thymosin-alpha 1) is an immunomodulating agent able to enhance the Thl immune response. It has been evaluated for its immunomodulatory activities and related therapeutic potential in several diseases, including chronic hepatitis B and C, AIDS, primary immunodeficiency diseases, depressed response to vaccination and cancer. | | Mechanism of action | The primary mechanism by which Thymalfasin operates involves bolstering the immune system. Thymosin Alpha-1, the active component of Thymalfasin, is known to enhance T-cell function. T-cells are a type of white blood cell crucial for adaptive immunity. By promoting the maturation and differentiation of these cells, Thymalfasin aids the body in mounting a more effective immune response against pathogens and malignant cells. Additionally, Thymalfasin has been observed to increase the production of various cytokines, including interleukin-2 (IL-2) and interferon-gamma (IFN-γ). These cytokines play a pivotal role in regulating immune responses and activating other immune cells. Furthermore, Thymalfasin has demonstrated the ability to enhance the activity of natural killer (NK) cells, which are essential for the innate immune response against virally infected cells and tumors. The peptide also exhibits anti-inflammatory properties, making it a multifaceted tool in the arsenal of immunotherapy. | | References | [1] A. Ciancio, & M. R. (2010). Thymalfasin in the treatment of hepatitis B and C. Annals of the New York Academy of Sciences, 1194 1, 141–146. https://doi.org/10.1111/j.1749-6632.2010.05487.x |
| | Thymalfasin Preparation Products And Raw materials |
|